Photocure Q1 2026 Earnings Report
Analysis based on 6 articles · First reported May 07, 2026 · Last updated May 07, 2026
Photocure's strong Q1 2026 results, driven by increased adoption of blue-light cystoscopy and significant milestone payments for Cevira approvals in China and Europe, are expected to positively impact its stock price. The potential reclassification of BLC equipment by the United States — Food and Drug Administration could further expand Photocure's commercial opportunities in the U.S. market, leading to long-term shareholder value.
Photocure reported strong financial results for the first quarter of 2026, with Hexvix/Cysview revenues of NOK 139.0 million and total revenues of NOK 264.6 million. The company's adjusted EBITDA reached NOK 15.3 million. Key drivers for this growth include accelerating adoption of blue-light cystoscopy (BLC) in North America and Europe, with 11 new Saphira towers installed in the United States and 75 Olympus Visera Elite III BLC systems in Europe. Photocure also recognized NOK 125.6 million in milestone payments, primarily from the approval of Cevira in China by the China — National Medical Products Administration and the European Union — European Medicines Agency's acceptance of its Marketing Authorization Application in Europe. A dispute exists with Asieris Pharmaceuticals regarding a portion of the milestone payment for Cevira's approval in China. Furthermore, the United States — Food and Drug Administration provided clarity on the reclassification pathway for OAY-related equipment, which Photocure anticipates will unlock a significantly larger commercial opportunity in the U.S. market. Photocure also made a minority investment in Vesica Health to advance its integrated diagnostics platform.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard